Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma

British Journal of Cancer

Volumn 79, Issue 11-12, 1999, Pages 1800-1805

  Assersohn, L ^a   Norman, A ^a   Cunningham, D ^a   Benepal, T ^a   Ross, P J ^a   Oates, J ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Colorectal cancer; Metastatic site; Prognostic

Indexed keywords

ALPHA INTERFERON; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; MITOMYCIN C; SERUM ALBUMIN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PERITONEUM METASTASIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0033038701     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6990287     Document Type: Article

References (29)

1. Advanced Colorectal Cancer Meta-Analysis Project (1992) Modulation of Fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10: 896-903
2. Allen-Mersh TG, Earlam S, Fordy C, Abrams K and Houghton J (1994) Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 344: 1255-1260
3. Buroker T, O'Connell M, Wieand S, Krook JE, Gerstner JB, Mailliard JA, Schaefer PL, Levitt R, Kardinal CG and Gesme DH (1994) Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12: 14-20
4. Cancer Research Campaign (1998) Factsheet 1.3 (incidence of cancer in males in UK) and 1.4 (incidence of cancer in females in UK).
5. Chang AE, Steinberg SM, Culnane M and White DE (1989) Determinants of survival in patients with unresectable colorectal liver metastases. J Surg Oncol 40: 245-251
6. Conti JA, Kemeny NE, Saltz LB, Andre AM, Grossano DD and Bertino JR (1995) Continuous infusion fluorouracil/leucovorin and bolus mitomycin C as a salvage regimen for patients with advanced colorectal cancer. Cancer 75: 769-774
7. Finan PJ, Marshall RJ, Cooper EH and Giles GR (1985) Factors affecting survival in patients presenting with synchronous hepatic metastases from colorectal cancer: a clinical and computer analysis. Br J Surg 72: 373-377
8. Fountzilas G, Gossios K, Zisiadis A, Svarna E, Skarlos D and Pavlidis N (1996). Prognostic variables in patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy. Med & Ped Oncol 26: 305-317
9. Gorlick R, Metzger R, Danenberg KD, Salonga D, Miles JS, Longo GSA, Fu J, Banerjee D, Klimstra D, Jhanwar S, Danenberg PV, Kemeny N and Bertino JR (1998) Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma. J Clin Oncol 16: 1465-1469
10. Hill M, Norman A, Cunningham D, Findlay M, Watson M, Nicolson V, Webb A, Middleton G, Ahmed F, Hickish T, Nicolson M, O'Brien M, Iveson T, Iveson A and Evans C (1995a) Impact of protracted venous infusion fluorouracil with or without interferon Alfa-2b on tumor response, survival and quality of life in advanced colorectal cancer. J Clin Oncol 13: 2317-2323
11. Hill M, Norman A, Cunningham D, Findlay M, Nicolson V, Hill A, Iveson A, Evans C, Joffe J, Nicolson M and Hickish T (1995b) Royal Marsden phase III trial of Fluorouracil with or without interferon Alfa-2b in advanced colorectal cancer. J Clin Oncol 13: 1297-1302
12. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV and Leichman L (1995) Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55: 1407-1412
13. Kosmidis PA, Tsavaris N, Skarlos D, Theocharis D, Samantas E, Pavlidis N, Briassoulis E and Fountzilas G (1996) Fluorouracil and leucovorin with or without interferon Alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. J Clin Oncol 14: 2682-2687
14. Kouri M, Pyrhonen S and Kuusela P (1992) Elevated CA19-9 as the most significant prognostic factor in advanced colorectal carcinoma. J Surg Oncol 49: 78-85
15. Kouri M, Nordling S, Kuusela P and Pythonen S (1993) Poor prognosis associated with elevated serum CA 19-9 level in advanced colorectal carcinoma, independent of DNA ploidy or SPF. Eur J Cancer 29A: 1691-1696
16. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, Bowsell W, Metzger R, Tan M and Danenberg PV (1997) Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15: 3223-3229
17. Mayer RJ (1992) Chemotherapy for metastatic colorectal cancer. Cancer 70: 1414-1424
18. Meta-analysis Group In Cancer (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16: 301-308
19. Miller AB, Hoogstraaten B, Staquet M and Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
20. Nordic Gastrointestinal Tumour Adjuvant Therapy Group (1992) Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 10: 904-911
21. Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Krook JE, Mailliard JA, Laurie J, Tschetter LK and Wiesenfeld M (1989) Biochemical modulation of Fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7: 1407-1418
22. Recchia F, Nuzzo A, Lalli A, Lombardo M, Di-Lullo L, Fabiani F, Fanini R, Venturoni L, Torchio P and Peretti G (1996) Randomized trial of 5-Fluorouracil and high-dose folinic acid with or without alpha-2b interferon in advanced colorectal cancer. Am J Clin Oncol 19: 301-304
23. Ross P, Norman A, Cunningham D, Webb A, Iveson T, Padhani A, Prendiville J, Watson M, Massey A and Oates J (1997) A prospective randomised trial of protracted venous infusion (PVI) 5-FU with or without mitomycin C (MMC) in advanced colorectal cancer. Annals Oncol 8: 995-1001
24. Scheithauer W, Rosen H, Kornek GV, Sebesta C and Depisch D (1993) Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 306: 752-755
25. Seymour MT, Slevin ML, Kerr DJ, Cunningham D, James RD, Ledermann JA, Perren TJ, McAdam WA, Harper PG, Neoptolemos JP, Nicholson M, Duffy AM, Stephens RJ, Stenning SP and Taylor I (1996) Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. J Clin Oncol 14: 2280-2288
26. Stangl R, Altendorf-Hofmann A, Charnley R and Scheele J (1994) Factors influencing the natural history of colorectal liver metastases. Lancet 343: 1405-1410
27. Steinberg J, Erlichman C, Gadalla T, Fine S and Wong A (1992) Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. Eur J Cancer 28A(ii): 1817-1820
28. Webb A, Scott-Mackie P, Cunningham D, Norman A, Andreyev J, O'Brien M and Bensted J (1995) The prognostic value of CEA, bHCG, AFP, CA125, CA19-9 and C-erb B-2, bHCG immunohistochemistry in advanced colorectal cancer. Annals Oncol 6: 581-587
29. Yeh KH, Shun CT, Chen CL, Lin JT, Lee WJ, Lee PH, Chen YC and Cheng AL (1998) High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 82: 1626-1631